Aandeel DARE DARÉ BIOSCIENCE, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Daré Bioscience, Inc.

Aandelen

DARE

US23666P1012

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 01-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,3299 USD +7,28% Intraday-grafiek van Daré Bioscience, Inc. +15,35% +6,76%
30/04 Daré Bioscience, Inc. sluit royalty tegeldemakingstransactie af met XOMA (US) LLC CI
30/04 XOMA Corporation (NasdaqGM:XOMA) heeft de overname van drie First-in-Category Assets van Daré Bioscience, Inc. (NasdaqCM:DARE) voor $22 miljoen afgerond. CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience, Inc. Announces Executive Changes
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned
Daré Bioscience Announces Executive Team and Board of Directors Changes
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers DARE
  4. Nieuws Daré Bioscience, Inc.
  5. Andere talen